Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29632797 | 0.97 | THRB (0.58) | THRBTHRA | |
| SCHEMBL29632801 | 0.85 | THRB (0.64) | THRBTHRA | |
| SCHEMBL29527302 | 0.84 | THRB (0.43) | THRBTHRA | |
| SCHEMBL23663170 | 0.83 | THRB (0.65) | THRBTHRA | |
| SCHEMBL29527489 | 0.81 | THRB (0.60) | THRBTHRA | |
| SCHEMBL29066190 | 0.81 | THRA (0.50) | THRBTHRA | |
| SCHEMBL29066178 | 0.81 | THRB (0.57) | THRBTHRA | |
| SCHEMBL24407922 | 0.80 | THRB (0.48) | THRBTHRA | |
| SCHEMBL29066245 | 0.80 | THRB (0.56) | THRBTHRA | |
| SCHEMBL29066204 | 0.79 | THRB (0.41) | THRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786532-B2 | 2-pyridones and methods of use thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| EP-4240730-A1 | 2-PYRIDONES AS THYROID HORMONE RECEPTOR MODULATORS | Aligos Therapeutics, Inc. (US) | 2023-09-13 | — | — | EP | disclosed |
| WO-2022099044-A1 | 2-PYRIDONES AS THYROID HORMONE RECEPTOR MODULATORS | ALIGOS THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| US-20220143032-A1 | 2-PYRIDONES AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143032-A1 | 2-PYRIDONES AND METHODS OF USE THEREOF | PSEN2, MAPT, PNPO | THRB 1462/4885THRA 2147/4885 |
| US-11786532-B2 | 2-pyridones and methods of use thereof | PSEN2, MAPT, PNPO | THRB 1462/4885THRA 2147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.